Ascenta Therapeutics

About:

Ascenta Therapeutics, a clinical-stage biopharmaceutical company, focuses on the discovery and development of new medicines to treat cancer.

Website: http://www.ascenta.com

Top Investors: Sofinnova Investments, U.S. Venture Partners, Scale Venture Partners, Domain Associates, Enterprise Partners

Description:

Ascenta Therapeutics is a privately-held, clinical stage biopharmaceutical company dedicated to the discovery and development of new medicines to treat cancer. Ascenta's current focus is a portfolio of novel, orally-active, small molecule drugs that restore the natural potential for cancer cells to undergo cell death (apoptosis).

Total Funding Amount:

$87.8M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Malvern, Pennsylvania, United States

Founded Date:

2003-01-01

Contact Email:

info(AT)ascenta.com

Founders:

Dajun Yang, Marc Lippman, Shaomeng Wang

Number of Employees:

51-100

Last Funding Date:

2010-02-06

IPO Status:

Private

Industries:

© 2025 bioDAO.ai